Some studies have found that, compared to patients with melanoma patients, patients with NSCLC and a history of prior lung radiation therapy may experience a higher incidence of pneumonia when treated with PD-1 inhibitors [80–82]. This evidence concerns the gene PDCD1 and susceptibility to pneumonia measurement.